COMBINATION OF A GABA-A ALPHA 2/3 AGONIST AND A SELECTIVE SEROTONIN REUPTAKE INHIBITOR

摘要

The present invention provides a pharmaceutical product comprising an SSRI and a non-sedating anxiolytic compound which is a modulator of the benzodiazepine binding site of the human GABAA receptor, having a binding affinity (Ki) for the alpha 3 subunit of the human GABAA receptor of 10 nM or less, which elicits at least a 40 % potentiation of the GABA EC20 response in stably transfected recombinant cell lines expressing the alpha 3 subunit of the human GABAA receptor, and which elicits at most a 30 % potentiation of the GABA EC20 response in stably transfected cell lines expressing the alpha 1 submit of the human GABAA receptor for simultaneous, separate or sequential administration.